Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Why Bruker Stock Tumbled by Almost 12% Wednesday
Why Bruker Stock Tumbled by Almost 12% Wednesday

Medical device and diagnostics company Bruker (NASDAQ: BRKR) wasn't looking like the cure for any investor's ailments on Wednesday. The stock was hit with an assertive sell-off from the market

3 Things You Need to Know if You Buy Pfizer Today
3 Things You Need to Know if You Buy Pfizer Today

There are a number of reasons to believe that Pfizer (NYSE: PFE) is an attractive dividend stock. The lofty 6.9% dividend yield is the obvious first reason, but the healthcare giant also has a long

Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?

The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching

HealthEquity Net Income Jumps 67% in Q2
HealthEquity Net Income Jumps 67% in Q2

HealthEquity (NASDAQ:HQY), a leading provider of Health Savings Account (HSA) custodial services in the United States, reported fiscal 2026 second-quarter earnings on Sept. 2. The release noted

Think It's Too Late to Buy This Leading Healthcare Stock? Here's the Biggest Reason Why There's Still Time
Think It's Too Late to Buy This Leading Healthcare Stock? Here's the Biggest Reason Why There's Still Time

UnitedHealth Group (NYSE: UNH) has attracted much attention over the past year, for both good and bad reasons. Recently, well-known value investors Warren Buffett of Berkshire Hathaway and Michael

3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever
3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever

A buoyant stock market that keeps reaching new heights is great for the stocks already in our brokerage accounts. After a few strongly positive years, though, finding stocks that pay high dividend

Pfizer's 7% Dividend: Income Gem or Value Trap?
Pfizer's 7% Dividend: Income Gem or Value Trap?

Pfizer (NYSE: PFE) has become the dividend investor's siren song. With shares down 31% over the past five years and a current yield of 7%, the pharmaceutical giant offers one of the juiciest payouts

AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network – Revenue increased by more than 20% in the first half of 2025 despite challenging conditions
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network – Revenue increased by more than 20% in the first half of 2025 despite challenging conditions
AEVIS VICTORIA SA (AEVS.SW) – Swiss Medical Network – Revenue increased by more than 20% in the first half of 2025 despite challenging conditions
3 No-Brainer Stocks to Buy Right Now
3 No-Brainer Stocks to Buy Right Now

Some decisions require lengthy deliberations and extensive analysis. Others don't.

Three Fool.com contributors think they've identified pharmaceutical stocks in the latter category. Here's why they

Better High-Yielding Dividend Stock: Realty Income vs. Pfizer
Better High-Yielding Dividend Stock: Realty Income vs. Pfizer

Dividend stocks are a great way for investors to generate passive income that can be more reliable and predictable than investing in stocks for pure appreciation. While there are no guarantees in

Prediction: This Monster Artificial Intelligence (AI) Chip Stock Will Soar in September (Hint: It's Not Nvidia)
Prediction: This Monster Artificial Intelligence (AI) Chip Stock Will Soar in September (Hint: It's Not Nvidia)

Over the past several weeks, investors have been bombarded with a wave of updates as companies reported earnings results for the second calendar quarter. For technology investors, artificial

3 Best Dividend Stocks to Buy Now
3 Best Dividend Stocks to Buy Now

One of the highest honors among dividend stocks is to be a Dividend Aristocrat®, which requires 25 consecutive years or more in annual increases. The title Dividend Aristocrat is such a big deal

7 Best Dividend Champions to Buy Now
7 Best Dividend Champions to Buy Now

Dividend Champions are long-term winners. These companies have grown their dividends for at least 25 straight years. They don't have to be members of the S&P 500 (SNPINDEX: ^GSPC), which broadens

1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP)
1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP)

Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even

If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today
If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

If you're looking for growth stocks that could make dramatic gains in a short amount of time, the healthcare sector has you covered. Recently, investment bank analysts have been pounding the table

EQS-News: Gerresheimer AG: Wolf Lehmann to take over CFO position at Gerresheimer on September 1, 2025
EQS-News: Gerresheimer AG: Wolf Lehmann to take over CFO position at Gerresheimer on September 1, 2025
EQS-News: Gerresheimer AG: Wolf Lehmann to take over CFO position at Gerresheimer on September 1, 2025
Why Viking Therapeutics Stock Popped Nearly 4% Today
Why Viking Therapeutics Stock Popped Nearly 4% Today

Numerous companies in the healthcare sector are feverishly busy developing obesity drugs, as these products have taken the medical world by storm. One of the more prominent developers

Stock Market Today: Nvidia Slips Despite Strong Earnings and Guidance
Stock Market Today: Nvidia Slips Despite Strong Earnings and Guidance

Nvidia (NASDAQ: NVDA) closed at $180.12, down 0.82%. Trading volume surged to 278 million shares, well above the 178 million three-month average. The chipmaker, valued at $4.4 trillion, traded as

This Small Artificial Intelligence (AI) Company Just Doubled Its Nvidia GPUs With 1 Massive Order
This Small Artificial Intelligence (AI) Company Just Doubled Its Nvidia GPUs With 1 Massive Order

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), IREN (NASDAQ: IREN), Advanced Micro Devices (NASDAQ: AMD), and other semiconductor stocks. To learn more, check out the

"Big Short" Investor Michael Burry Just Followed Warren Buffett Into This Plummeting Healthcare Stock. Should You Follow His Lead?
"Big Short" Investor Michael Burry Just Followed Warren Buffett Into This Plummeting Healthcare Stock. Should You Follow His Lead?

Michael Burry is best known as one of the earliest and most vocal investors to predict the housing collapse of 2008 -- a prescient call that earned him notoriety and a Hollywood portrayal by

2 Dividend Stocks to Hold for the Next 10 Years
2 Dividend Stocks to Hold for the Next 10 Years

The healthcare industry is a good place to look for strong dividend-paying stocks. Many companies in the sector offer products that are consistently in demand, regardless of the state of the

EQS-News: Gerresheimer expands financial flexibility to implement growth strategy
EQS-News: Gerresheimer expands financial flexibility to implement growth strategy
EQS-News: Gerresheimer expands financial flexibility to implement growth strategy
Agilent Reports 10% Revenue Jump in Q3
Agilent Reports 10% Revenue Jump in Q3

Agilent Technologies (NYSE:A), a global leader in laboratory instruments and scientific solutions for life sciences and diagnostics, released its Q3 fiscal 2025 results on Aug. 27, 2025. The company

Veeva Systems Lifts Outlook on CRM Wins
Veeva Systems Lifts Outlook on CRM Wins

Veeva Systems(NYSE:VEEV) reported fiscal second quarter 2026 results on August 27, 2025, delivering $789 million in revenue and raising full-year billings guidance by $35 million. The quarter